Travelzoo has announced four new exclusive vacation deals for its Canadian club members, featuring trips to Amsterdam, the Canary Islands, Quebec, and Stockholm. These packages include flights, hotels, and additional perks, with discounts ranging from 30% to 40% compared to booking directly. The offers cater to travel enthusiasts looking for vetted, affordable travel experiences. Interested travelers can join the Travelzoo club to access these and other deals.
The story about exclusive travel deals for Canadian club members provides context for consumer cyclical stocks on Pluang. For readers following this sector, here is Pluang's market snapshot as of Oct 01, 2026 21:12 WIB: out of 112 priced Consumer Cyclical-sector US stocks, 43 rose and 67 fell today. Notable movers include DHI (D R Horton Inc) at USD 132.79 with a 1-day change of -2.82% and a typical hold time of 46 days, LEN (Lennar Corporation) at USD 79.41 with a 1-day change of -2.67% and 100% buy order activity, and GGR (Gogoro Inc) at USD 3.05 with a 1-day change of -2.56% and a typical hold time of 14 days.
The CHMP of the European Medicines Agency has recommended approval for Johnson & Johnson's TALVEY (talquetamab) combined with daratumumab, with or without pomalidomide, for treating adults with relapsed or refractory multiple myeloma who have had at ...
The European Medicines Agency's CHMP has recommended approving Johnson & Johnson's TALVEY® (talquetamab) combined with daratumumab for treating relapsed or refractory multiple myeloma earlier in the treatment process, starting from the second line. T...
The European Medicines Agency's CHMP has recommended approval for Johnson & Johnson's TALVEY® (talquetamab) in combination with daratumumab for treating relapsed or refractory multiple myeloma (RRMM) in patients who have had at least one prior therap...
Fortrea Holdings and Omico have formed a partnership to enhance precision oncology research in Australia by linking cancer patients to biomarker-matched clinical trials. This collaboration combines Fortrea's oncology trial expertise with Omico's Prec...
Fortrea Holdings and Omico have formed a partnership to accelerate precision oncology research in Australia by combining Fortrea's clinical trial expertise with Omico's Precision Oncology Screening Platform (PrOSPeCT). This collaboration aims to impr...
